Dr. Francois X. Claret

Department of Systems Biology, Division of Cancer Medicine

University of Texas, USA

Associate Professor



1997 Postdoc., School of Medicine, University of California

1993 Ph.D., Molecular Biology, University of Lausanne

Publications (Selected)

  1. Vu TT, Sliwkowski MX, Claret FX. Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochimica et Biophysica Acta - Reviews on Cancer. In Press.
  2. Astaves V, Lekakis L, Drakos I, Leventaki V, Jones D, Feretzaki M, Liakou C, Korapati A, Horie R, Panayiotidis P, Gorgoulis V, Patsouris E, Medeiros JL, Claret FX, Rassidakis G. The oncogenic JunB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma. British Journal of Hematology. In Press.
  3. Zhou F, Meng S, Song H, Claret FX.. Dickkopf-1 is a key regulator of myeloma bone disease: Opportunities and challenges for therapeutic intervention. Blood Reviews 27(6):261–267, 9/2013. PMID: 24054128.
  4. Zhou F, Shen Q, Claret FX.. Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. Journal of Leukocyte Biology 94(3):423-9, 9/2013. PMID: 23715741.
  5. Pan Y, Wang M, Bu X, Zuo Y, Wang S, Wang D, Liu Q, Xu T, Wang C, Claret FX, Yang H. Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma. BMC cancer 13(1):323, 7/2013. PMID: 23815987.
  6. Pan Y, Zhang Q, Atsaves V, Yang H, Claret FX. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene 32(22):2756-66, 5/2013. PMCID: PMC3566273.
  7. Echalier A*, Pan Y*, Birol M, Tavernier N, Pintard L, Hoh F, Ebel C, Galophe N, Claret FX, Dumas C. (*) Equal contribution. Insights into the regulation of the human Cop9 signalosome catalytic subunit, CSN5/Jab1. Proceedings of the National Academy of Sciences U S A (PNAS) 110(4):1273-8, 1/2013. PMID: 23288897.
  8. Pan Y, Zhou F, Zhang R, Claret FX. Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma. PLOS ONE 8(1):e54565,, January 29, 2013. PMCID: PMCPMC3558509.
  9. Vu T and Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Frontiers in Cancer Molecular Targets and Therapeutics. 2(62), 6/2012. PMCID: PMC3376449.
  10. Pan Y, Zhang Q, Tian L, Wang X, Fan X, Zhang H, Claret FX, Yang H. Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma. Cancer Research 72(7):1890-1900, 4/2012. PMCID: PMC3460549.
  11. Zhang Q, Claret FX. Phosphatases: the new brakes for cancer development? Enzyme Research 2012(659649), 2012. e-Pub 10/2011. PMCID: PMC3206369.
  12. Shackleford TJ, Zhang Q, Tian L, Vu TT, Korapati AL, Baumgartner A, Le XF, Liao WS, Claret FX.. STAT3 and CCAAT/Enhancer Binding Protein beta (C/EBP-β) regulate Jab1/CSN5 expression in mammary carcinoma cells. Breast Cancer Research 13(3):R65, 6/2011. PMCID: PMC3218954.
  13. Drakos E, Rassidakis G, Schlette E, Li J, Singh RJ, Vega F, Claret FX, Ford J, Medeiros LJ.. Activation of p53 Pathway by MDM2 Inhibitor Nutlin-3a Overcomes BCL2 Overexpression in a Preclinical Model of Diffuse Large B-cell Lymphoma Associated with t(14;18)(q32;q21). Leukemia (Nature Publishing Group) 5(25):856-867, 2011. PMCID: PMC3094765.
  14. Drakos E, Leventaki V, Atsaves V, Schlette EJ, Lin P, Vega F, Claret FX, Medeiros JL, Rassidakis GZ.. Expression of Serine 194-phosphorylated FADD strongly correlates with proliferation in B-cell Non-Hodgkin lymphomas. Human Pathology 42(8):1117-24, 2011. PMID: 21315423.
  15. Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC Jr.. The Role of p27Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells. Journal of the National Cancer Institute (JNCI) 103(18):1403-22, 2011. PMCID: PMC3176777.
  16. Tian L, Peng G, Parant JM, Leventaki V, Drakos I, Zhang Q, Parker-Thornburg J, Shackleford T, Dai H, Lin, S-Y. Lozano G, Rassidakis, GZ, Claret FX.. Essential Roles of Jab1 in Cell Survival, Spontaneous DNA Damage, and DNA Repair. Oncogene (Nature Publishing Group) 29(46):6125-6137, 2010. PMCID: PMC3495558.
  17. Shackleford T, Claret FX. JAB1: a new player in cell cycle control and cancer. Cell Division 5(1):1-14, 2010. PMCID: PMC2976740.
  18. Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G. JNK-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer. Clinical Cancer Research 1(16):184-94, 2010. PMID: 20028751.
  19. Shin S, Asano T, Yao Y, Krishnan K, Korc M, Sabapathy K, Menter DG, Claret FX, Abbruzzese JL and Reddy SA. Activator Protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel AKT-mediated mechanism. Molecular Cancer Research 7(5):745-54, 2009. PMID: 19435822.
  20. Estrella VC, Eder AM, Liu S, Pustilnik TB, Tabassam FH, Claret FX, Gallick GE, Mills GB, Wiener JR. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. International Journal of Oncology 31(2):441-9, 2007. PMID: 17611702.
  21. Leventaki V, Drakos E, Medeiros LJ, Lim MS, Elenitoba-Johnson KS, Claret FX and Rassidakis GZ.. NPM-ALK oncogenic kinase promotes cell cycle progression through activation of JNK/c-Jun signalling in anaplastic large cell lymphoma. Blood 110(5):6589-89, 2007. PMID: 17416736.
  22. Vega F, Medeiros JF, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Research 66(13):6589-97, 2006. PMID: 16818631.
  23. Kim HJ, Chakravarti N, Oridate N, Choe C, Claret FX, Lotan R. N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene 25(19):2785-94, 2006. PMCID: PMC1458365.
  24. Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chiao P, Ho L, Evans DB, Claret FX. Potential Role of Jun Activation Domain-Binding Protein 1 as a Negative Regulator of p27kip1 in Pancreatic Adenocarcinoma. Cancer Research 66(17):8581-9, 2006. PMCID: PMC1780177.
  25. Zhang Q, Tian L, Mansouri A, Korapati AL, Johnson TJ, Claret FX. Inducible expression of a degradation-resistant form of p27Kip1 causes growth arrest and apoptosis in breast cancer cells. FEBS Letters 579(18):3932-40, 2005. PMCID: PMC1366489.

Profile Details

Free SCIRP Newsletters
Copyright © 2006-2021 Scientific Research Publishing Inc. All Rights Reserved.